51. Treatment progress of severe aplastic anemia
- Author
-
Ji Yanping and Sun Zimin
- Subjects
antithymocyte globulin ,umbilical cord blood hematopoietic stem cell transplantation ,human leukocyte antigen ,haploidentical hematopoietic stem cell transplantation ,overall survival ,lcsh:R ,immunosuppressive therapy ,graft-versus-host disease ,lcsh:Medicine ,allogeneic hematopoietic stem cell transplantation ,severe aplastic anemia - Abstract
Severe aplastic anemia (SAA) is a rare type of bone marrow hematopoietic failure, which is associated with toxic T lymphocyte-based immune dysfunction, abnormal hematopoietic microenvironment and damage of hematopoietic stem cells in patients. SAA characterized by acute onset, rapid progression and high mortality rate, which requires rapid and stable recovery of the patients' hematopoietic function. In this article, the therapeutic progresses on immunosuppressive therapy (IST), sibling human leukocyte antigen (HLA)-matched allogenetic hematopoietic stem cell transplantation (allo-HSCT), replacement of donor hematopoietic stem cell transplantation and unrelated umbilical cord blood hematopoietic stem cell transplantation (UCBT) for SAA were reviewed.
- Published
- 2020